Products Empagliflozin is commercially available in the form of film-coated tablets. It was approved in the EU, the United States, and many countries in 2014 (Jardiance). Empagliflozin is also combined fixed with metformin (Jardiance Met) as well as with linagliptin (Glyxambi). Trijardy XR is a fixed combination of empagliflozin, linagliptin, and metformin. Structure and properties … Empagliflozin
Products Tofogliflozin was approved in Japan in 2014 (initial registration, Apleway, Deberza). The drug is not currently registered in many countries. Structure and properties Tofogliflozin (C22H26O6, Mr = 386.4 g/mol) Effects Tofogliflozin has antidiabetic and antihyperglycemic properties. It is a selective inhibitor of sodium–glucose co-transporter 2 (SGLT2). This transporter is responsible for the reabsorption of … Tofogliflozin
Products Dapagliflozin is commercially available in the form of film-coated tablets (Forxiga). It was approved in the EU in 2012 and in the United States and many countries in 2014. Dapagliflozin is also combined fixed with metformin (Xigduo XR). A fixed combination with saxagliptin was approved in 2017 (Qternmet film-coated tablets). Qternmet XR is a … Dapagliflozin
Structure and properties Remogliflozin (C23H32N2O8, Mr = 464.5 g/mol) is present in drugs as remogliflozinetabonate, an ester prodrug of remogliflozin. Effects Remogliflozin has antidiabetic and antihyperglycemic properties. It is a selective inhibitor of sodium–glucose co-transporter 2 (SGLT2). This transporter is responsible for the reabsorption of glucose at the proximal tubule of the nephron. Inhibition leads … Remogliflozin
Products Ipragliflozin is not currently registered in many countries. It was first approved in Japan in 2014 (Suglat). Structure and properties Ipragliflozin (C21H21FO5S, Mr = 404.5 g/mol) is a benzthiophene derivative. Effects Ipragliflozin has antidiabetic and antihyperglycemic properties. It is a selective inhibitor of sodium–glucose co-transporter 2 (SGLT2). This transporter is responsible for the reabsorption … Ipragliflozin
Products Ertugliflozin was approved in the United States in 2017 and in the EU and many countries in 2018 in film-coated tablet form (Steglatro). The agent is also combined fixed with sitagliptin (Steglujan) and with metformin (Segluromet). Structure and properties Ertugliflozin (C22H25ClO7, Mr = 436.9 g/mol) is present in the drug as ertugliflozin-L-pyroglutamic acid, a … Ertugliflozin
Structure and properties Sergliflozin (C20H24O7, Mr = 376.4 g/mol) exists as sergliflozinetabonate, an ester prodrug of sergliflozin. Effects Sergliflozin has antidiabetic and antihyperglycemic properties. It is a selective inhibitor of sodium–glucose co-transporter 2 (SGLT2). This transporter is responsible for the reabsorption of glucose at the proximal tubule of the nephron. Inhibition leads to increased excretion … Sergliflozin
